Loading...
•
Mar 31, 2024
Replimune Q4 2024 Earnings Report
Replimune reported financial results for the fiscal fourth quarter and year ended March 31, 2024, and provided a business update.
Key Takeaways
Replimune announced financial results for the fiscal fourth quarter and year ended March 31, 2024. The company believes that existing cash, cash equivalents and short-term investments, as of March 31, 2024 will enable the Company to fund operations into the second half of 2026.
Shared investigator-assessed 12-month IGNYTE data at ASCO.
Official primary analysis by independent central review later in the second quarter.
Phase 3 confirmatory IGNYTE-3 clinical trial design has been agreed with the FDA, with patient enrollment planned to initiate in the second half of the year prior to the submission of our BLA for RP1.
Completed a successful Type C meeting with the FDA to align on our CMC plans ahead of the intended BLA.
Replimune
Replimune
Forward Guidance
Replimune believes that existing cash, cash equivalents and short-term investments, as of March 31, 2024 will enable the Company to fund operations into the second half of 2026.